Photocure ASA
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHCUF research report →
Companywww.photocure.com
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix.
- CEO
- Daniel Schneider
- IPO
- 2013
- Employees
- 99
- HQ
- Oslo, NO
Price Chart
Valuation
- Market Cap
- $196.62M
- P/E
- 20.70
- P/S
- 2.60
- P/B
- 3.02
- EV/EBITDA
- 7.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.48%
- Op Margin
- 26.90%
- Net Margin
- 12.55%
- ROE
- 16.63%
- ROIC
- 21.62%
Growth & Income
- Revenue
- $532.28M · 1.31%
- Net Income
- $-1,518,137 · 68.44%
- EPS
- $-0.06 · 68.06%
- Op Income
- $109.98M
- FCF YoY
- -42.43%
Performance & Tape
- 52W High
- $7.39
- 52W Low
- $4.32
- 50D MA
- $7.11
- 200D MA
- $6.38
- Beta
- 0.65
- Avg Volume
- 3
Get TickerSpark's AI analysis on PHCUF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PHCUF Coverage
We haven't published any research on PHCUF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PHCUF Report →